Список литературы к Главe 1

1. Rai K.R. Progress in chronic lymphocytic leukemia: a historical perspective // Baillieres Clin Hematol. 1993. Vol. 6. P. 757–765.

2. Gunz F.W. The dread leukemias and the lymphomas: their nature and their prospects // Blood, Pure and Eloquent / ed. M.M. Wintrobe. New York : McGraw Hill, 1980. P. 511–546.

3. Hamblin T. Historical aspects of chronic lymphocytic leukaemia // Br. J. Haematol. 2000. Vol. 111, N 4. P. 1023–1034.

4. Galton D.A.G. The Natural History of Chronic Lymphocytic Leukemia. Cambridge : Cambridge University, 1963.

5. Craigie D. Case of disease and enlargement of the spleen in which death took place from the presence of purulent matter in the blood // Edinb. Med. Surg. J. 1845. Vol. 64. P. 400–412.

6. Bennett J.H. Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood // Edinb. Med. Surg. J. 1845. Vol. 64. P. 413–423.

7. Bennett J.H. Leucocythemia or white cell blood // Relation to the Physiology and Pathology of the Lymphatic Glandular System. Edinburgh : Sutherland and Knox, 1852.

8. Virchow R. Weisses Blut // Neue Notizen aus dem Gebiete der Natur­ und Heilkunde. 1845. Bd 36. S. 151–156.

9. Einhorn M. Uber das Verhalten der Lymphocyten zu den weissen Blutkorperschen Inaugural­Dissertat. Berlin, 1881.

10. Turk W. Ein System der Lymphomatosen // Klin. Wochenschr. 1903. Bd 16. S. 1073–1085.

11. Osler W. Leukaemia // Principles and Practice of Medicine. 7th ed. / ed. D. Appleton. New York, 1909. P. 731–738.

12. Minot G., Isaacs R. Lymphatic leukemia: age incidence, duration, and benefit derived from irradiation // Bost. Med. Surg. J. 1924. Vol. 191. P. 1–10.

13. Leavell B.S. Chronic leukemia: a study of incidence and factors influencing the duration of life // Am. J. Med. Sci. 1938. Vol. 196. P. 329–340.

14. Galton D.A.G. The pathogenesis of chronic lymphocytic leukaemia // Can. Med. Assoc. J. 1966. Vol. 94. P. 1005–1010.

15. Dameshek W. Chronic lymphocytic leukemia – an accumulative disease of immunologically incompetent lymphocytes // Blood. 1967. Vol. 29. P. 566–584.

16. Galton D.A.G. et al. Clinical trials of p­(DI­2­chloroethylamino)­phenylbutyric acid(CB 1348) in malignant lymphoma // Br. Med. J. 1955. Vol. 12. P. 1172–1176.

17. Shaw R.K. et al. A study of prednisone therapy in chronic lymphocytic leukemia // Blood. 1961. Vol. 17. P. 182–189.

18. Rai K.R., Sawitsky A., Cronkite E.P. Clinical staging of chronic lymphocytic leukemia // Blood. 1975. Vol. 46. P. 219–234.

19. Rai K.R. A critical analysis of staging in CLL // Chronic Lymphocytic Leukemia. Recent Progress and Future Directions / eds R.P. Gale, K.R. Rai. New York, 1987. P. 253–264.

20. Binet J.L., Leporrier M., Dighiero G. A clinical staging system for chronic lymphocytic leukemia // Cancer. 1977. Vol. 40. P. 855–864.

21. Binet J.L. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. Vol. 48, N 1. P. 198–206.

22. International Workshop on CLL. Chronic lymphocytic leukaemia: proposals for a revised staging system // Br. J. Haematol. 1981. Vol. 48. P. 365–367.

23. International Workshop on CLL. Recommendations for diagnosis, staging, and response criteria // Ann. Intern. Med. 1989. Vol. 110. P. 236–238.

24. Marti G.E., Zenger V. The natural history of CLL // Chronic Lymphocytic Leukemia. Totowa, NJ : Humana Press, 2004. P. 3–54.

25. Molica S. et al. Timing of diagnosis and lymphocyte accumulation patterns in chronic lymphocytic leukemia: analysis of their clinical significance // Eur. J. Haematol. 2009. Vol. 44, N 5. P. 277–281.

26. Zwiebel J.A., Cheson B.D. Chronic lymphocytic leukemia: staging and prognostic factors // Semin. Oncol. 1998. Vol. 25. P. 42–59.

27. Shen A. et al. Human heavy­chain variable region gene family nonrandomly rearranged in familial chronic lymphocytic leukemia // Proc. Natl Acad. Sci. USA. 1987. Vol. 84. P. 8563–8567.

28. Kipps T.J. et al. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia // Proc. Natl Acad. Sci. USA. 1989. Vol. 86, N 15. P. 5913–5917.

29. Damle R.N. et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia // Blood. 1999. Vol. 94. P. 1840–1847.

30. Stilgenbauer S., Lichter P., Dohner H. Genomic aberrations in B­CLL chronic lymphocytic leukemia // Chronic Lymphoid Leukemias. 2nd ed. / ed. B.D. Cheson. New York : Marcel Dekker, 2001. P. 353–376.

31. Keating M.J., Kantarjian H., Talpaz M. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia // Blood. 1989. Vol. 74. P. 19–25.

32. Keating M.J. et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia // J. Clin. Oncol. 1991. Vol. 9, N 1. P. 44–49.

33. O’Brien S. et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis­derived prognostic model for response to treatment // Blood. 1993. Vol. 82, N 6. P. 1695–1700.

34. Rai K.R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 24. P. 1750–1757.

35. Maloney D.G., Liles T.M., Czerwinski D.K. Phase I clinical trial using escalating single­dose infusion of chimeric anti­CD20 monoclonal antibody (IDEC­C2B8) in patients with recurrent B­cell lymphoma // Blood. 1994. Vol. 84. P. 2457–2466.

36. Maloney D.C., Grillo­Lopez A.J., White C.A. IDEC­C2B8 (rituximab) anti­CD20 monoclonal antibody therapy in patients with relapsed low­grade non­Hodgkin’s lymphoma // Blood. 1997. Vol. 90. P. 2188–2195.

37. McLaughlin P. et al. Rituximab chimeric anti­CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four­dose treatment program // J. Clin. Oncol. 1998. Vol. 16, N 8. P. 2825–2833.

38. O’Brien S.M. et al. Rituximab dose­escalation trial in chronic lymphocytic leukemia // J. Clin. Oncol. 2001. Vol. 19, N 8. P. 2165–2170.

39. Byrd J.C. et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B­cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712) // Blood. 2003. Vol. 101, N 1. P. 6–14.

40. Wierda W. et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia // J. Clin. Oncol. 2005. Vol. 23, N 18. P. 4070–4078.

41. Keating M.J. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia // J. Clin. Oncol. 2005. Vol. 23, N 18. P. 4079–4088.

42. Eichhorst B. et al. First­line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open­label, randomised, phase 3, non­inferiority trial // Lancet Oncol. 2016. Vol. 17, N 7. P. 928–942.

43. Goede V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions // N. Engl. J. Med. 2014. Vol. 370, N 12. P. 1101–1110.

44. Casola S. et al. B cell receptor signal strength determines B cell fate // Nat. Immunol. 2004. Vol. 5, N 3. P. 317–327.

45. Pan Z. et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase // ChemMedChem. 2007. Vol. 2, N 1. P. 58–61.

46. Advani R.H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI­32765) has significant activity in patients with relapsed/refractory B­cell malignancies // J. Clin. Oncol. 2013. Vol. 31, N 1. P. 88–94.

47. Byrd J.C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2013. Vol. 369, N 1. P. 32–42.

48. Robertson L.E. et al. Bcl­2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome // Leukemia. 1996. Vol. 10, N 3. P. 456–459.

49. Souers A.J. et al. ABT­199, a potent and selective BCL­2 inhibitor, achieves antitumor activity while sparing platelets // Nat. Med. 2013. Vol. 19, N 2. P. 202–208.